| Title |
Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers
|
|---|---|
| Published in |
Pediatric Drugs, August 2014
|
| DOI | 10.1007/s40272-014-0085-1 |
| Pubmed ID | |
| Authors |
Steven E. Lipshultz, Melissa B. Diamond, Vivian I. Franco, Sanjeev Aggarwal, Kasey Leger, Maria Verônica Santos, Stephen E. Sallan, Eric J. Chow |
| Abstract |
In the US, children diagnosed with cancer are living longer, but not without consequences from the same drugs that cured their cancer. In these patients, cardiovascular disease is the leading cause of non-cancer-related morbidity and mortality. Although this review focuses on anthracycline-related cardiomyopathy in childhood cancer survivors, the global lifetime risk of other cardiovascular diseases such as atherosclerosis, arrhythmias and intracardiac conduction abnormalities, hypertension, and stroke also are increased. Besides anthracyclines, newer molecularly targeted agents, such as vascular endothelial growth factor receptor and tyrosine kinase inhibitors, also have been associated with acute hypertension, cardiomyopathy, and increased risk of ischemic cardiac events and arrhythmias, and are summarized here. This review also covers other risk factors for chemotherapy-related cardiotoxicity (including both modifiable and non-modifiable factors), monitoring strategies (including both blood and imaging-based biomarkers) during and following cancer treatment, and discusses the management of cardiotoxicity (including prevention strategies such as cardioprotection by use of dexrazoxane). |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 17% |
| Unknown | 5 | 83% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 83% |
| Unknown | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | <1% |
| United States | 1 | <1% |
| Italy | 1 | <1% |
| Unknown | 105 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 17% |
| Researcher | 12 | 11% |
| Student > Ph. D. Student | 11 | 10% |
| Student > Bachelor | 11 | 10% |
| Student > Postgraduate | 8 | 7% |
| Other | 18 | 17% |
| Unknown | 30 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 50 | 46% |
| Biochemistry, Genetics and Molecular Biology | 7 | 6% |
| Nursing and Health Professions | 6 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Psychology | 2 | 2% |
| Other | 0 | 0% |
| Unknown | 38 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2021.
All research outputs
#3,247,692
of 25,101,232 outputs
Outputs from Pediatric Drugs
#52
of 584 outputs
Outputs of similar age
#31,783
of 241,747 outputs
Outputs of similar age from Pediatric Drugs
#3
of 7 outputs
Altmetric has tracked 25,101,232 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 584 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,747 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.